Logo image of IBIO

IBIO INC (IBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IBIO - US4510337086 - Common Stock

2.2 USD
-0.01 (-0.45%)
Last: 1/16/2026, 8:00:01 PM
2.25 USD
+0.05 (+2.27%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

2

IBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. IBIO has a bad profitability rating. Also its financial health evaluation is rather negative. IBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • IBIO had negative earnings in the past year.
  • IBIO had a negative operating cash flow in the past year.
  • IBIO had negative earnings in each of the past 5 years.
  • IBIO had a negative operating cash flow in each of the past 5 years.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • IBIO has a worse Return On Assets (-79.26%) than 66.29% of its industry peers.
  • IBIO has a Return On Equity of -123.50%. This is in the lower half of the industry: IBIO underperforms 60.23% of its industry peers.
Industry RankSector Rank
ROA -79.26%
ROE -123.5%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • IBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

  • IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

  • IBIO has an Altman-Z score of -18.91. This is a bad value and indicates that IBIO is not financially healthy and even has some risk of bankruptcy.
  • IBIO has a worse Altman-Z score (-18.91) than 81.25% of its industry peers.
  • IBIO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • IBIO has a Debt to Equity ratio of 0.05. This is comparable to the rest of the industry: IBIO outperforms 40.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -18.91
ROIC/WACCN/A
WACC8.88%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 1.59 indicates that IBIO should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.59, IBIO is not doing good in the industry: 79.73% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.59 indicates that IBIO should not have too much problems paying its short term obligations.
  • IBIO has a Quick ratio of 1.59. This is in the lower half of the industry: IBIO underperforms 78.98% of its industry peers.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.59
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

  • IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.07%, which is quite impressive.
  • IBIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 77.78%.
  • IBIO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.59% yearly.
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A

3.2 Future

  • IBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.09% yearly.
  • IBIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.56% yearly.
EPS Next Y76.89%
EPS Next 2Y35.73%
EPS Next 3Y22.02%
EPS Next 5Y11.09%
Revenue Next Year-25%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • IBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • IBIO's earnings are expected to grow with 22.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.73%
EPS Next 3Y22.02%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for IBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IBIO INC

NASDAQ:IBIO (1/16/2026, 8:00:01 PM)

After market: 2.25 +0.05 (+2.27%)

2.2

-0.01 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)02-09
Inst Owners47.09%
Inst Owner Change0%
Ins Owners3.56%
Ins Owner Change0%
Market Cap49.48M
Revenue(TTM)400.00K
Net Income(TTM)-18.38M
Analysts86
Price Target4.61 (109.55%)
Short Float %18.01%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.87%
Min EPS beat(2)-50.12%
Max EPS beat(2)-31.61%
EPS beat(4)1
Avg EPS beat(4)-19.5%
Min EPS beat(4)-50.12%
Max EPS beat(4)6.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.78%
PT rev (3m)4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.87%
EPS NY rev (1m)0%
EPS NY rev (3m)25.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 123.7
P/FCF N/A
P/OCF N/A
P/B 3.33
P/tB 6.16
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.02
BVpS0.66
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.26%
ROE -123.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.06%
Cap/Sales 4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.59
Altman-Z -18.91
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)216.31%
Cap/Depr(5y)243.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y76.89%
EPS Next 2Y35.73%
EPS Next 3Y22.02%
EPS Next 5Y11.09%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A
Revenue Next Year-25%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
EBIT growth 1Y-80.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.52%
OCF growth 3YN/A
OCF growth 5YN/A

IBIO INC / IBIO FAQ

What is the ChartMill fundamental rating of IBIO INC (IBIO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IBIO.


What is the valuation status for IBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to IBIO INC (IBIO). This can be considered as Overvalued.


Can you provide the profitability details for IBIO INC?

IBIO INC (IBIO) has a profitability rating of 0 / 10.